Find a Clinical Trial

Physicians

Learn how we help support and foster independent practices.

Visit Site

Patients

Learn how we help make patient care our number one priority.

Visit Site

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Lung Cancer

Clinical Trial at: Texas Oncology - Paris

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Paris

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Rectal Cancer

Clinical Trial at: Texas Oncology - Paris

A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

  • Details

ClinicalTrials.gov ID: NCT03597295
Diagnosis Type: NA
USOR Number: 18134

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Paris

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

GI Stromal Tumor (GIST)

Clinical Trial at: Texas Oncology - Paris

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

  • Details

ClinicalTrials.gov ID: NCT03465722
Diagnosis Type: NA
USOR Number: 18016

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Paris

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

  • Details

ClinicalTrials.gov ID: NCT03535740
Diagnosis Type: NSCLC
USOR Number: 18076

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Paris

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

  • Details

ClinicalTrials.gov ID: NCT03706365
Diagnosis Type: NA
USOR Number: 18128

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Paris

POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

  • Details

ClinicalTrials.gov ID: NCT03280303
Diagnosis Type: NA
USOR Number: 16128

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Paris

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Texas Oncology - Paris

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Texas Oncology - Paris

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Paris

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

  • Details

ClinicalTrials.gov ID: NCT02952534
Diagnosis Type: NA
USOR Number: 16237

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Paris

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)

  • Details

ClinicalTrials.gov ID: NCT02975934
Diagnosis Type: NA
USOR Number: 16238

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Paris

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

  • Details

ClinicalTrials.gov ID: NCT02488967
Diagnosis Type: NA
USOR Number: 15146

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Sherman

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Sherman

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

  • Details

ClinicalTrials.gov ID: NCT03906071
Diagnosis Type: NA
USOR Number: 19018

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Sherman

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Sherman

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

  • Details

ClinicalTrials.gov ID: NCT03535740
Diagnosis Type: NSCLC
USOR Number: 18076

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Sherman

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

  • Details

ClinicalTrials.gov ID: NCT03706365
Diagnosis Type: NA
USOR Number: 18128

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Sherman

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Pages

Patient Sub Menu

Patients